Military.. Cerus receives $1.4 million to support development of INTERCEPT red blood cell system Cerus Company announced today that it has received an additional $1.4 million from the U.S. Section of Defense to aid advanced advancement of the business’s pathogen inactivation technology for crimson blood cells. The INTERCEPT reddish colored blood cell system can be a pathogen inactivation product Cerus is usually developing to prevent the transmitting of infectious diseases through red blood cell transfusions.S. Division of Defense is still a strong supporter of pathogen inactivation,’ said Dr. Laurence Corash, Cerus’ chief medical officer. ‘This award allows Cerus to support advanced advancement of the INTERCEPT Blood System for red blood cells.’ The award, granted by the U.S.Companies violate the necessity that this can be restrict to scientific and factual matters. Health facilities and wellness workers continue being targeted. Sponsorship of medical seminars, conferences and associations of doctors is now more widespread. The main bottle and teat companies are evaluated also. Country summary reviews with the title Appear What They’re Doing have already been prepared for the next countries: China Egypt Indonesia UK Zimbabwe, Tanzania and Ghana Latin America and Caribbean Related StoriesCardiovascular disease risk is now able to become predicted for teensAggressive blood circulation pressure treatment can reduce dangers of cardiovascular disease and deathResearchers discover significant hyperlink between breast tumor and nutrition, explore brand-new preventative treatmentTypical firm responses to reviews of violations can be found on the infant Milk Actions website.